MAIA Biotechnology, Inc. (MAIA)
| Market Cap | 82.11M +57.5% |
| Revenue (ttm) | n/a |
| Net Income | -26.85M |
| EPS | -0.61 |
| Shares Out | 60.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 227,998 |
| Open | 1.400 |
| Previous Close | 1.390 |
| Day's Range | 1.325 - 1.400 |
| 52-Week Range | 0.870 - 3.190 |
| Beta | 0.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 10, 2026 |
About MAIA
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Financial Performance
Financial StatementsNews
MAIA Biotechnology files $150M mixed securities shelf
16:17 EDT MAIA Biotechnology (MAIA) files $150M mixed securities shelf
MAIA Biotechnology Registration statement: Registration filing
MAIA Biotechnology filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnol...
MAIA Biotechnology Quarterly report: Q2 2026
MAIA Biotechnology has published its Q2 2026 quarterly earnings report on August 10, 2026.
MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion
MAIA Biotechnology (MAIA) announced initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorp...
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-tre...
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical...
MAIA Biotechnology opens third clinical site in U.S. for Phase 2 THIO-101 trial
MAIA Biotechnology (MAIA) announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University, is activated and now enrolling patients. Th...
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE NEWS...
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected $7...
MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial
MAIA Biotechnology (MAIA) provided a patient enrollment update for its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line treatment for advanced n...
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer
MAIA Biotechnology receives FDA clearance for amendment to IND application
MAIA Biotechnology (MAIA) announced that the U.S. Food and Drug Administration has cleared an amendment to update its investigational new drug application which enables MAIA to open U.S. enrollment fo...
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA
MAIA Biotechnology announces open market purchases by CEO, director
MAIA Biotechnology (MAIA) announced that its founder and CEO Vlad Vitoc, M.D. and Director Stan Smith, Ph.D. have increased their ownership positions through open market purchases. Approximately 72,70...
MAIA Biotechnology Announces Open Market Purchases by CEO and Director
CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunothera...
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunothera...
MAIA Biotechnology Transcript: AGM 2026
The meeting confirmed a quorum, elected two directors for three-year terms, and ratified the appointment of independent auditors. Shareholders participated virtually, with questions addressed during and after the meeting.
MAIA Biotechnology Proxy statement: Proxy filing
MAIA Biotechnology filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
MAIA Biotechnology Quarterly report: Q1 2026
MAIA Biotechnology has published its Q1 2026 quarterly earnings report on May 11, 2026.
MAIA Biotechnology Proxy statement: Proxy filing
MAIA Biotechnology filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
MAIA Biotechnology secures funding for clinical trial of ateganosine
MAIA Biotechnology (MAIA) announced that net proceeds from its $33M public offering of common stock in March are expected to fully fund the company’s ongoing pivotal Phase 3 clinical trial…
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential
MAIA Biotechnology Proxy statement: Proxy filing
MAIA Biotechnology filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
MAIA Biotechnology Proxy statement: Proxy filing
MAIA Biotechnology filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.